Press Releases

LAWRENCEVILLE, N.J. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.

Data show d ose - dependent suppression of immun e- suppressive agents GEN-1 stimulate s the immune system through the production of CD4 and CD8 cells C hemotherapy R esponse Score tripled in the two highest doses of GEN-1 and is double that of chemotherapy alone LAWRENCEVILLE, N.J.

OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene- M ediated Immunotherapy is Safe and Demonstrates an Acceptable   R isk/ B enefit W hen Administered O ver a Six-Month   Period   with   Up to 17 D oses LAWRENCEVILLE, N.J.

VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage

LAWRENCEVILLE, N.J. , July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , Celsion GmbH , a wholly owned subsidiary of Celsion Corporation , a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox study with ThermoDox ® in

Celsion GmbH   will manage current and future cancer studies with Thermo D ox ® Celsion   continues its strategic   focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J. , June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on

Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and   Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. , June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based

Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J. , June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy

25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez , MD LAWRENCEVILLE, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines,

49% of S hares V oted, Q uorum N ot E stablished   To Hold Annual Meeting Polls Remain Open Stockholders H olding U nvoted Proxies A re S trongly E ncouraged to V ote T heir S hares LAWRENCEVILLE, N.J. , June 04, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage